Henry Schein (NASDAQ:HSIC) Announces Earnings Results

Henry Schein (NASDAQ:HSIC) announced its quarterly earnings data on Tuesday. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.36 by $0.20, Zacks reports. The business had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.48 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%. The business’s revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.38 earnings per share.

Here are the key takeaways from Henry Schein’s conference call:

• U.S. dental merchandise sales rose 8.6%, including 7% internal local-currency growth, driven primarily by volume and claimed market-share gains among private practices and emerging DSOs.
• Adjusted non-GAAP diluted EPS increased 19.1% to $1.37, while non-GAAP operating margin expanded 20 basis points to 8.03%; management said its value-creation program remains on track to deliver more than $200 million of operating-income improvement, including a $125 million run rate by year-end 2026.
• Henry Schein raised 2026 non-GAAP EPS guidance to $5.50-$5.56 from $5.29-$5.39 and expects adjusted EBITDA growth in the high single digits, citing stronger underlying performance and a $0.19-per-share tariff-refund benefit.
• Management plans targeted fourth-quarter investments in customer acquisition, share of wallet, company-owned and exclusive products, and cloud-based practice-management software, while continuing share repurchases; it bought back $125 million of stock in the quarter and had approximately $330 million remaining under authorization.
• The U.S. dental market and patient traffic were described as stable, but discretionary procedures showed some pressure from out-of-pocket costs; medical growth was also restrained by weaker point-of-care diagnostic and flu/COVID vaccine demand, partly offset by 11.4% growth in Home Solutions.

Henry Schein Trading Up 6.7%

Shares of NASDAQ HSIC traded up $5.49 during trading hours on Wednesday, hitting $87.99. 431,009 shares of the company traded hands, compared to its average volume of 1,334,141. The company’s 50 day moving average price is $86.35 and its 200 day moving average price is $81.18. Henry Schein has a 12 month low of $68.70 and a 12 month high of $92.18. The stock has a market capitalization of $9.81 billion, a price-to-earnings ratio of 25.62, a price-to-earnings-growth ratio of 1.56 and a beta of 0.87. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Wall Street Analyst Weigh In

Several analysts recently issued reports on HSIC shares. Barclays reissued an “overweight” rating and set a $100.00 target price (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Barrington Research set a $104.00 price target on Henry Schein in a research note on Wednesday, August 5th. Piper Sandler increased their price objective on shares of Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Leerink Partners set a $92.00 price objective on shares of Henry Schein and gave the company a “market perform” rating in a report on Wednesday, October 14th. Finally, BMO Capital Markets began coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price objective on the stock. Nine research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Henry Schein currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.27.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.56 per share, beating analyst estimates, while sales rose 4% year over year to about $3.47 billion. Henry Schein also raised its full-year 2026 earnings guidance. Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance
• Negative Sentiment: Revenue was slightly below expectations, and reports of patients delaying discretionary dental procedures raised concerns about demand. That softness appears to have overshadowed the earnings beat and improved outlook. Henry Schein Sees Pressure From Discretionary Dental Delays

About Henry Schein

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.